<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Gen Med</journal-id><journal-id journal-id-type="iso-abbrev">Int J Gen Med</journal-id><journal-id journal-id-type="publisher-id">International Journal of General Medicine</journal-id><journal-title-group><journal-title>International Journal of General Medicine</journal-title></journal-title-group><issn pub-type="epub">1178-7074</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29773952</article-id><article-id pub-id-type="pmc">5947106</article-id><article-id pub-id-type="doi">10.2147/IJGM.S144385</article-id><article-id pub-id-type="publisher-id">ijgm-11-175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Remote ischemic preconditioning in myocardial protection in hemodialysis patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bacci</surname><given-names>Marcelo R</given-names></name><xref ref-type="aff" rid="af1-ijgm-11-175">1</xref><xref ref-type="corresp" rid="c1-ijgm-11-175"/></contrib><contrib contrib-type="author"><name><surname>Vasconcelos</surname><given-names>Livia Y</given-names></name><xref ref-type="aff" rid="af1-ijgm-11-175">1</xref></contrib><contrib contrib-type="author"><name><surname>Murad</surname><given-names>Neif</given-names></name><xref ref-type="aff" rid="af2-ijgm-11-175">2</xref></contrib><contrib contrib-type="author"><name><surname>Chagas</surname><given-names>Antonio Carlos P</given-names></name><xref ref-type="aff" rid="af2-ijgm-11-175">2</xref></contrib><contrib contrib-type="author"><name><surname>Capuano</surname><given-names>Ana Carolina</given-names></name><xref ref-type="aff" rid="af1-ijgm-11-175">1</xref></contrib><contrib contrib-type="author"><name><surname>Alves</surname><given-names>Beatriz CA</given-names></name><xref ref-type="aff" rid="af3-ijgm-11-175">3</xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Edimar C</given-names></name><xref ref-type="aff" rid="af4-ijgm-11-175">4</xref></contrib><contrib contrib-type="author"><name><surname>Azzalis</surname><given-names>Ligia A</given-names></name><xref ref-type="aff" rid="af4-ijgm-11-175">4</xref></contrib><contrib contrib-type="author"><name><surname>Junqueira</surname><given-names>Virginia BC</given-names></name><xref ref-type="aff" rid="af4-ijgm-11-175">4</xref></contrib><contrib contrib-type="author"><name><surname>Fonseca</surname><given-names>Fernando LA</given-names></name><xref ref-type="aff" rid="af3-ijgm-11-175">3</xref><xref ref-type="aff" rid="af4-ijgm-11-175">4</xref></contrib></contrib-group><aff id="af1-ijgm-11-175">
<label>1</label>Department of General Practice</aff><aff id="af2-ijgm-11-175">
<label>2</label>Department of Cardiology</aff><aff id="af3-ijgm-11-175">
<label>3</label>Clinical Analysis Laboratory of Faculdade de Medicina do ABC, Santo Andr&#x000e9;, SP, Brazil</aff><aff id="af4-ijgm-11-175">
<label>4</label>Department of Pharmaceutical Sciences, Universidade Federal de Sao Paulo, Diadema, SP, Brazil</aff><author-notes><corresp id="c1-ijgm-11-175">Correspondence: Marcelo R Bacci, Department of General Practice, Faculdade de Medicina do ABC, Av. Principe de Gales n 821, Vila Valpara&#x000ed;so, Santo Andr&#x000e9;, SP, ZIP 09060-650, Brazil, Tel + 55 11 9 8193 7005, Email <email>mrbacci@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>08</day><month>5</month><year>2018</year></pub-date><volume>11</volume><fpage>175</fpage><lpage>178</lpage><permissions><copyright-statement>&#x000a9; 2018 Bacci et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>Remote ischemic preconditioning (RIPC) is a procedure that generates a brief period of ischemia followed by reperfusion. The role of RIPC in protecting myocardial ischemia during hemodialysis is not yet established. The aim of the study was to evaluate RIPC myocardial protection as evaluated by ultrasensitive I troponin in hemodialysis outpatients.</p></sec><sec><title>Patients and methods</title><p>A double-blind randomized trial with two groups: intervention submitted to RIPC and control group without RIPC. Intervention group received RIPC in three consecutive hemodialysis sessions. Blood samples were taken before and after each session. Blood urea nitrogen for calculation of single-pool Kt/v and ultrasensitive I troponin were measured to evaluate dialysis adequacy and myocardial injury.</p></sec><sec><title>Results</title><p>A total of 47 patients were randomized. About 60.8% were men and 54% were diabetic. The mean single-pool Kt/v was 1.51 in the intervention group and 1.49 in control. The ultrasensitive troponin I measured no significant change from the time of collection: before or after dialysis.</p></sec><sec><title>Conclusion</title><p>The RIPC applied in three consecutive sessions did not demonstrate superiority to control, therefore another study tested RIPC in 12 consecutive sessions with a positive result in myocardial protection. In our study, more than half of the patients were diabetic. Diabetic patients have a trend to show a lower response to RIPC because of the greater presence of collateral coronary circulation. In summary, in this model there was no interference of RIPC in ultrasensitive troponin I values, but troponin had a high negative predictive value for myocardial infarction in all tested models.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>hemodialysis</kwd><kwd>chronic kidney disease</kwd><kwd>cardiac troponin</kwd><kwd>remote ischemic preconditioning</kwd><kwd>myocardial infarction</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Remote ischemic preconditioning (RIPC) is defined as brief transient episodes of ischemia followed by a prolonged sustained episode of ischemia and reperfusion in the heart. It was first described by Murry et al in 1986, when they showed that brief ischemic episodes in dogs by the experimental occlusion of the left coronary artery reduced infarct extension caused by the occlusion of the circumflex artery and subsequent reperfusion.<xref rid="b1-ijgm-11-175" ref-type="bibr">1</xref> It was observed that these induced ischemic periods followed by reperfusion promote cardioprotection in situations in which this prolonged ischemic event is expected, like in cardiac surgeries, transplants or even percutaneous coronary angioplasty.<xref rid="b2-ijgm-11-175" ref-type="bibr">2</xref></p><p>Kadkhodaee et al reported protective effects in the kidney by pre- and post- conditioning in ischemic situations and induced reperfusion.<xref rid="b3-ijgm-11-175" ref-type="bibr">3</xref> Besides all other risk factors, patients on hemodialysis have a common complication from the procedure associated with myocardial ischemia. With the prolonged decrease of oxygen supply, a left ventricular dysfunction can be observed in the long run, resulting in cardiac insufficiency and an increase in mortality.<xref rid="b4-ijgm-11-175" ref-type="bibr">4</xref></p><p>A recent study reveals that conventional hemodialysis, besides being associated with endothelial injury, oxidative stress and high inflammatory activity, can induce microcirculation injury with consequent critical ischemia and tissue damages during the procedure.<xref rid="b4-ijgm-11-175" ref-type="bibr">4</xref>, <xref rid="b5-ijgm-11-175" ref-type="bibr">5</xref></p><p>It is known that cardiac troponin I (cTnI) and cardiac troponin T (cTnT) levels are usually elevated and related to mortality in such cases. A recent meta-analysis concluded that the elevation of cTnI and cTnT represents a 2.64- and 1.74-fold increase in mortality, respectively.<xref rid="b6-ijgm-11-175" ref-type="bibr">6</xref> The aim of this study was to analyze the RIPC effect in myocardial injury by means of the measurement of cTnI in patients with chronic kidney disease on hemodialysis.</p></sec><sec sec-type="methods|subjects"><title>Patients and methods</title><sec sec-type="methods"><title>Study design</title><p>This is a randomized clinical trial. Patients were divided into two groups: experiment and control. Randomization was performed according to the list generated by the website <ext-link ext-link-type="uri" xlink:href="http://www.randomizatiom.com">www.randomizatiom.com</ext-link>, which was accessed only by the nurse in charge of the dialysis. Researchers remained blinded as to which group each patient belonged to. Patients on medications for the treatment of pre-existing diseases were not washed out.</p><p>Hemodialysis sessions were set to 3:30 hours, with blood flow of 300 mL/min, dialysate flow of 500 mL/min, sodium concentration of 140 mEq/L and bicarbonate of 34 mEq/L. The ultrafiltration value was defined according to the individual need of each patient. Written informed consent was obtained from each participant included in this study; this study and its protocol were conducted in accordance with the Declaration of Helsinki, and the study was approved by the Faculdade de Medicina do ABC Ethics Committee (CAAE number 45920015.5.0000.0082).</p></sec><sec sec-type="methods"><title>Study interventions</title><p>The ischemic preconditioning consisted of a 5-minute interruption of the brachial blood flow using a Tycos sphygmomanometer (Welch Allyn, Skaneateles Falls, NY, USA) inflated to 200 mmHg or until the distal blood flow was interrupted; subsequent deflation followed with the same rest period, and the procedure was repeated twice, totaling 30 minutes of intervention. The contralateral arm was chosen, next to the functioning arteriovenous fistula, and in the absence of the fistula, the right arm was used. The intervention occurred in the beginning of the dialysis session. The intervention group underwent three consecutive sessions of RIPC, whereas control group underwent none.</p></sec><sec><title>Interesting outcomes</title><p>The primary outcome was the decrease in ultrasensitive cTnI level when intervention and control groups were compared. The secondary outcome was mortality by any cause at time points 30 and 90 days, hospitalization due to cardiovascular event defined as acute coronary syndrome, pulmonary thromboembolism or cerebrovascular accident.</p></sec><sec><title>Variables of interest</title><p>The analysis of biochemical markers was carried out using blood samples collected at 2 and 7 days prior to the allocation, in the beginning of the first hemodialysis session, after the initial allocation.</p><p>Plasma cTnI levels were measured by ELISA assay, and their cutoff values were defined according to the constructed calibration curve. Values above the 99th percentile were considered altered.</p><p>For dialysis adequacy, the values of single-pool Kt/V and the urea reduction ratio (URR) were considered adequate if they were &#x02265;1.2 and 65%, respectively.</p><p>The analysis of the inflammatory markers was performed using the ELISA method. Cutoff values were set on a method-by-method basis according to each used kit, following each manufacturer&#x02019;s instructions.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>This was a 40-patient pilot study. The sample was divided into two groups: 20 in the control group and 20 in the intervention group.</p><p>Qualitative variables were presented with absolute and relative frequencies and analyzed by the chi-square test. Shapiro&#x02013;Wilk test was used to verify the normality of quantitative variables. As the distribution was not normal, median values, along with the respective 95% confidence intervals, were used. Quantitative variable between groups were analyzed with the Mann&#x02013;Whitney test, and Wilcoxon test was applied to verify if there were differences in the collections before and after each moment, confidence interval was 95%. Data Analysis and Statistical Software for Professionals (Stata), version 11.0, was the statistical package used.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The mean age in the control group was 63.9 years (SD&#x000b1;15.8), and in the intervention group it was 52.1 years (SD&#x000b1;21.5). All of the patients from both groups suffered from systemic hypertension. Diabetes was present in 60.8% of the patients in the intervention group and in 65.2% in the control group.</p><p><xref ref-type="table" rid="t1-ijgm-11-175">Table 1</xref> shows the characterization of the samples, taking parameters like gender, Kt/V, hemoglobin and ferritin into consideration.</p><p><xref ref-type="table" rid="t2-ijgm-11-175">Table 2</xref> shows the mean values of troponin pre- and post-dialysis in control and intervention groups. Interestingly, between the moments of pre- and post-dialysis the significance value was &#x0003c;0.05 (<italic>p</italic>&#x0003c;0.05) according to the Wilcoxon test, demonstrating that the RIPC did not have the expected effect.</p><p>In <xref ref-type="table" rid="t3-ijgm-11-175">Table 3</xref> it can be observed that there were no significant variations in the point estimation for urea, URR and troponin between control and intervention groups.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>It is known that chronic kidney disease patients on hemodialysis, even those without acute coronary disease, have high serum levels of troponin.</p><p>So far, very few management strategies have been proposed to reduce myocardial damage caused by hemodialysis. Remote ischemic preconditioning is one of the propositions.<xref rid="b7-ijgm-11-175" ref-type="bibr">7</xref>,<xref rid="b8-ijgm-11-175" ref-type="bibr">8</xref></p><p>Troponin is the biomarker of choice for the analysis of myocardial ischemia due to the fact that it is an enzyme specific to the cardiac muscle that plays an important role in the muscle contraction process; moreover, it practically has no relation with skeletal muscles. Most of the studies use troponin T (TnT) as a marker; studies using troponin I (TnI) are not only few but also short-term, with a small number of patients included.<xref rid="b9-ijgm-11-175" ref-type="bibr">9</xref></p><p>A 2012 study on the predictive value of troponin in patients on hemodialysis revealed a strong discrepancy between TnT and TnI values, which can be explained by their molecular mechanisms, like structure, molecular weight and half-life.<xref rid="b10-ijgm-11-175" ref-type="bibr">10</xref> Besides, the kinetics of enzyme release in the circulation after the alterations in myocyte membrane permeability can be different, and there is a divergence between the clearance of both enzymes Once released in the circulation, TnI becomes more susceptible to modifications owing to phosphorylation, oxidation and proteolysis.</p><p>Factors like aggressive ultrafiltration and intradialytic hypotension are associated with the aggravation of the myocardial ischemic condition during a hemodialysis session owing to the significant alterations in the coronary flow. Repeated injuries induced by ischemia followed by reperfusion cause alterations in motility and loss of contractility, which may lead to myocardial fibrosis and irreversible left ventricular systolic dysfunction.<xref rid="b11-ijgm-11-175" ref-type="bibr">11</xref></p><p>Burton et al showed that nearly 50% of patients on hemodialysis developed alterations in regional myocardial motility, and also that the mortality rate among these patients increased in the subsequent 12 months.<xref rid="b4-ijgm-11-175" ref-type="bibr">4</xref></p><p>No RIPC benefits, performed in three consecutive hemodialysis sessions in this study, could be observed. However, Park et al reported its beneficial effects in 12 consecutive hemodialysis sessions, when a decrease in TnT levels could be observed.<xref rid="b12-ijgm-11-175" ref-type="bibr">12</xref></p><p>This study faced some limitations. First, the number of sessions was lower than in other published studies, and it is not surely known how many interventions are necessary to obtain such benefits. The presence of diabetes is a positive predictive factor for higher cardiovascular mortality. Moreover, coronary collateral circulation in diabetic patients is higher due to the presence of ischemia, a factor that may be responsible for the lower response rate in patients undergoing RIPC. The studied sample included a diabetic population of &#x0003e;50%.<xref rid="b5-ijgm-11-175" ref-type="bibr">5</xref>, <xref rid="b13-ijgm-11-175" ref-type="bibr">13</xref></p><p>In sum, in the model of three consecutive hemodialysis sessions, no significant reduction in ultrasensitive troponin I concentrations could be observed when remote ischemic preconditioning was applied.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ijgm-11-175"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Jennings</surname><given-names>RB</given-names></name><name><surname>Reimer</surname><given-names>KA</given-names></name></person-group><article-title>Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium</article-title><source>Circulation</source><year>1986</year><volume>74</volume><issue>5</issue><fpage>1124</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">3769170</pub-id></element-citation></ref><ref id="b2-ijgm-11-175"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>B</given-names></name><name><surname>Ovize</surname><given-names>M</given-names></name><name><surname>Kloner</surname><given-names>RA</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Regional ischemic preconditioning protects remote virgin myocardium from subsequent sustained coronary occlusion</article-title><source>Circulation</source><year>1993</year><volume>87</volume><issue>3</issue><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">7680290</pub-id></element-citation></ref><ref id="b3-ijgm-11-175"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadkhodaee</surname><given-names>M</given-names></name><name><surname>Seifi</surname><given-names>B</given-names></name><name><surname>Najafi</surname><given-names>A</given-names></name><name><surname>Sedaghat</surname><given-names>Z</given-names></name></person-group><article-title>First report of the protective effects of remote per- and postconditioning on ischemia/reperfusion-induced renal injury</article-title><source>Transplantation</source><year>2011</year><volume>92</volume><issue>10</issue><fpage>e55</fpage><pub-id pub-id-type="pmid">22067215</pub-id></element-citation></ref><ref id="b4-ijgm-11-175"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>JO</given-names></name><name><surname>Jefferies</surname><given-names>HJ</given-names></name><name><surname>Selby</surname><given-names>NM</given-names></name><name><surname>McIntyre</surname><given-names>CW</given-names></name></person-group><article-title>Hemodialysis-induced cardiac injury: determinants and associated outcomes</article-title><source>Clin J Am Soc Nephrol</source><year>2009</year><volume>4</volume><issue>5</issue><fpage>914</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">19357245</pub-id></element-citation></ref><ref id="b5-ijgm-11-175"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benhamou</surname><given-names>Y</given-names></name><name><surname>Begarin</surname><given-names>L</given-names></name><name><surname>David</surname><given-names>N</given-names></name><etal/></person-group><article-title>Detection of microcirculatory impairment by transcutaneous oxymetry monitoring during hemodialysis: an observational study</article-title><source>BMC Nephrol</source><year>2014</year><volume>15</volume><issue>4</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24386889</pub-id></element-citation></ref><ref id="b6-ijgm-11-175"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalaji</surname><given-names>FR</given-names></name><name><surname>Albitar</surname><given-names>S</given-names></name></person-group><article-title>Predictive value of cardiac Troponin T and I in hemodialysis patients</article-title><source>Saudi J Kidney Dis Transpl</source><year>2012</year><volume>23</volume><issue>5</issue><fpage>39</fpage><lpage>945</lpage></element-citation></ref><ref id="b7-ijgm-11-175"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassanov</surname><given-names>N</given-names></name><name><surname>Nia</surname><given-names>AM</given-names></name><name><surname>Caglayan</surname><given-names>E</given-names></name><name><surname>Er</surname><given-names>F</given-names></name></person-group><article-title>Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option?</article-title><source>J Am Soc Nephrol</source><year>2014</year><volume>25</volume><issue>2</issue><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">24309187</pub-id></element-citation></ref><ref id="b8-ijgm-11-175"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><article-title>Cardioprotection: chances and challenges of its translation to the clinic</article-title><source>Lancet</source><year>2013</year><volume>381</volume><issue>9861</issue><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">23095318</pub-id></element-citation></ref><ref id="b9-ijgm-11-175"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>A</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>Mucsi</surname><given-names>I</given-names></name><name><surname>Barre</surname><given-names>PE</given-names></name><name><surname>Sniderman</surname><given-names>AD</given-names></name></person-group><article-title>Elevated troponin I levels but not low grade chronic inflammation is associated with cardiac-specific mortality in stable hemodialysis patients</article-title><source>BMC Nephrol</source><year>2013</year><volume>14</volume><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">24206774</pub-id></element-citation></ref><ref id="b10-ijgm-11-175"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artunc</surname><given-names>F</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name><name><surname>Breidthardt</surname><given-names>T</given-names></name><etal/></person-group><article-title>Sensitive troponins &#x02013; which suits better for hemodialysis patients? Associated factors and prediction of mortality</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>10</issue><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="b11-ijgm-11-175"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>B</given-names></name><name><surname>Ovize</surname><given-names>M</given-names></name><name><surname>Kloner</surname><given-names>RA</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name></person-group><article-title>Regional ischemic preconditioning protects remote virgin myocardium from subsequent sustained coronary occlusion</article-title><source>Circulation</source><year>1993</year><volume>87</volume><issue>3</issue><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">7680290</pub-id></element-citation></ref><ref id="b12-ijgm-11-175"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Ann</surname><given-names>SH</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning in hemodialysis: a pilot study</article-title><source>Heart Vessels</source><year>2014</year><volume>29</volume><issue>1</issue><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">23532306</pub-id></element-citation></ref><ref id="b13-ijgm-11-175"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venugopal</surname><given-names>V</given-names></name><name><surname>Laing</surname><given-names>CM</given-names></name><name><surname>Ludman</surname><given-names>A</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Hausenloy</surname><given-names>D</given-names></name></person-group><article-title>Effect of remote ischemic preconditioning on acute kidney injury in non-diabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials</article-title><source>Am J Kidney Dis</source><year>2010</year><volume>56</volume><issue>6</issue><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="pmid">20974511</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-ijgm-11-175" position="float"><label>Table 1</label><caption><p>Characterization of samples according to the studied groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Studied Groups</th><th colspan="2" valign="top" align="left" rowspan="1">Groups
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="tfn2-ijgm-11-175">*</xref></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Control</th><th valign="top" align="left" rowspan="1" colspan="1">Intervention</th></tr></thead><tbody><tr><td colspan="4" valign="top" align="left" rowspan="1">Gender, n (%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">9.0 (40.9)</td><td valign="top" align="left" rowspan="1" colspan="1">8.0 (34.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.672<xref ref-type="table-fn" rid="tfn2-ijgm-11-175">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">13.0 (59.1)</td><td valign="top" align="left" rowspan="1" colspan="1">15.0 (65.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Kt/V</td><td valign="top" align="left" rowspan="1" colspan="1">1.5 (1.1&#x02013;1.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.5 (1.1&#x02013;1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.846<xref ref-type="table-fn" rid="tfn3-ijgm-11-175">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hemoglobin, g/dL</td><td valign="top" align="left" rowspan="1" colspan="1">10.6 (10.4&#x02013;11.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11.1 (10.8&#x02013;11.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.190<xref ref-type="table-fn" rid="tfn3-ijgm-11-175">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Albumin, g/dL</td><td valign="top" align="left" rowspan="1" colspan="1">3.8 (3.6&#x02013;4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (3.9&#x02013;4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.010<xref ref-type="table-fn" rid="tfn3-ijgm-11-175">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ferritin, ug/L</td><td valign="top" align="left" rowspan="1" colspan="1">560.0 (364.9&#x02013;563.5)</td><td valign="top" align="left" rowspan="1" colspan="1">375.0 (278.1&#x02013;391.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.076<xref ref-type="table-fn" rid="tfn3-ijgm-11-175">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ijgm-11-175"><p><bold>Notes:</bold> Confidence interval of 95% shown in brackets;</p></fn><fn id="tfn2-ijgm-11-175"><label>*</label><p>chi-square;</p></fn><fn id="tfn3-ijgm-11-175"><label>**</label><p>Mann&#x02013;Whitney test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ijgm-11-175" position="float"><label>Table 2</label><caption><p>Point estimation (interval estimation) of troponin concentration according to the moments in control and intervention groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">cTn</th><th colspan="3" valign="top" align="left" rowspan="1">Control
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Intervention
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Pre</th><th valign="top" align="left" rowspan="1" colspan="1">Post</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="tfn5-ijgm-11-175">*</xref></th><th valign="top" align="left" rowspan="1" colspan="1">Pre</th><th valign="top" align="left" rowspan="1" colspan="1">Post</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="tfn5-ijgm-11-175">*</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Troponin 1</td><td valign="top" align="left" rowspan="1" colspan="1">0.010 (0.006&#x02013;0.016)</td><td valign="top" align="left" rowspan="1" colspan="1">0.009 (0.006&#x02013;0.023)</td><td valign="top" align="left" rowspan="1" colspan="1">0.631</td><td valign="top" align="left" rowspan="1" colspan="1">0.007 (0.006&#x02013;0.012)</td><td valign="top" align="left" rowspan="1" colspan="1">0.007 (0.006&#x02013;0.011)</td><td valign="top" align="left" rowspan="1" colspan="1">0.152</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Troponin 2</td><td valign="top" align="left" rowspan="1" colspan="1">0.010 (0.006&#x02013;0.014)</td><td valign="top" align="left" rowspan="1" colspan="1">0.011 (0.006&#x02013;0.018)</td><td valign="top" align="left" rowspan="1" colspan="1">0.634</td><td valign="top" align="left" rowspan="1" colspan="1">0.009 (0.006&#x02013;0.017)</td><td valign="top" align="left" rowspan="1" colspan="1">0.006 (0.006&#x02013;0.014)</td><td valign="top" align="left" rowspan="1" colspan="1">0.987</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Troponin 3</td><td valign="top" align="left" rowspan="1" colspan="1">0.011 (0.006&#x02013;0.018)</td><td valign="top" align="left" rowspan="1" colspan="1">0.013 (0.007&#x02013;0.027)</td><td valign="top" align="left" rowspan="1" colspan="1">0.024</td><td valign="top" align="left" rowspan="1" colspan="1">0.007 (0.006&#x02013;0.018)</td><td valign="top" align="left" rowspan="1" colspan="1">0.006 (0.006&#x02013;0.009)</td><td valign="top" align="left" rowspan="1" colspan="1">0.136</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-ijgm-11-175"><p><bold>Notes:</bold> Values expressed in median (confidence interval of 95%);</p></fn><fn id="tfn5-ijgm-11-175"><label>*</label><p>Wilcoxon test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ijgm-11-175" position="float"><label>Table 3</label><caption><p>Point estimation of concentration variation of urea, troponin and urea reduction ratio between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Markers</th><th colspan="2" valign="top" align="left" rowspan="1">Groups
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="tfn8-ijgm-11-175">**</xref></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Control</th><th valign="top" align="left" rowspan="1" colspan="1">Intervention</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Urea<xref ref-type="table-fn" rid="tfn7-ijgm-11-175">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">63.50 (36.86&#x02013;89.35)</td><td valign="top" align="left" rowspan="1" colspan="1">75.75 (35.86&#x02013;104.52)</td><td valign="top" align="left" rowspan="1" colspan="1">0.672</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Troponin<xref ref-type="table-fn" rid="tfn7-ijgm-11-175">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;0.001 (&#x02013;0.0064&#x02013;0.0021)</td><td valign="top" align="left" rowspan="1" colspan="1">0.001 (&#x02013;0.0014&#x02013;0.0014)</td><td valign="top" align="left" rowspan="1" colspan="1">0.441</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urea reduction ratio<xref ref-type="table-fn" rid="tfn7-ijgm-11-175">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;0.650 (&#x02013;8.074&#x02013;11.427)</td><td valign="top" align="left" rowspan="1" colspan="1">4.500 (&#x02013;8.090&#x02013;13.901)</td><td valign="top" align="left" rowspan="1" colspan="1">0.503</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-ijgm-11-175"><p><bold>Notes:</bold> Values expressed in median (confidence interval of 95%);</p></fn><fn id="tfn7-ijgm-11-175"><label>*</label><p>variation between the first and last collection;</p></fn><fn id="tfn8-ijgm-11-175"><label>**</label><p>Wilcoxon test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>